Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gisselbrecht, C.
Right arrow Articles by Diebold, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gisselbrecht, C.
Right arrow Articles by Diebold, J.
Related Collections
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, Vol. 92 No. 1 (July 1), 1998: pp. 76-82

Prognostic Significance of T-Cell Phenotype in Aggressive Non-Hodgkin's Lymphomas

By Christian Gisselbrecht, Philippe Gaulard, Eric Lepage, Bertrand Coiffier, Josette Brière, Corinne Haioun, Dominique Cazals-Hatem, André Bosly, Luc Xerri, Hervé Tilly, Françoise Berger, Reda Bouhabdallah, and Jacques Diebold for the Groupe d'Etudes des Lymphomes de l'Adulte (GELA)

From the Institut d'Hématologie, Hôpital Saint-Louis, Paris; Département de Pathologie, Hôpital Henri-Mondor, Créteil; Unité d'Information Médicale, Hôpital Henri-Mondor, Paris; Service d'Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite; Service d'Anatomie Pathologique, Hôpital Necker, Paris; Hôpital de jour d'Hématologie, Hôpital Henri-Mondor, Créteil; Service d'Anatomie Pathologique, Hôpital Saint-Louis, Paris; Institut Paoli-Calmette, Marseille; Centre Henri-Becquerel, Rouen; Hôpital Edouard-Herriot, Lyon; Institut Paoli-Calmette, Marseille; Service d'Anatomie Pathologique, Hôtel Dieu, Paris, France; and Clinique Universitaire de Mont Godinne, Yvoir, Belgium.


    ABSTRACT
Abstract
Introduction
Methods
Results
Discussion
References

Peripheral T-cell lymphomas (PTCL) have been generally reported to have a worse prognosis than B-cell lymphomas (BCL). Because of their heterogeneity and scarcity, the outcomes of the different histological subtypes have not been compared. From October 1987 to March 1993, 1,883 patients with diffuse aggressive non-Hodgkin's lymphomas (NHL) included in the LNH87 protocol could be assessed for both morphology and immunophenotyping. Among them, 288 (15%) had PTCL and 1,595 (85%) had BCL. According to the Kiel classification, most PTCL were classified as angioimmunoblastic (AIL; 23%), pleomorphic medium and large T-cell (PML; 49%), or anaplastic large cell (ALCL; 20%) lymphomas. Comparing PTCL with BCL patients, the former had more disseminated disease (78% v 58%), B symptoms (57% v 40%), bone marrow involvement (31% v 17%), skin involvement (21% v 4%), and increased beta 2-microglobulin (50% v 34%), whereas BCL patients had more bulky disease (41% v 26%). According to the International Prognostic Index (IPI), PTCL and BCL scores were, respectively: 0 factors, 13% and 15%; 1 factor, 17% and 22%; 2 factors, 24% and 25%; >= 3 factors, 45% and 37% (P = .09). For BCL and PTCL, respectively, complete remission rates were 63% and 54% (P = .004); the 5-year overall survival (OS) rates were 53% and 41% (P = .0004) and event-free survival (EFS) rates were 42% and 33% (P < .0001). Comparison of the different histological subtypes of lymphoma showed that the 5-year OS rate for T-ALCL (64%) was superior to those of other PTCL (35%) as well as diffuse large B-cell (53%) NHL. When multivariate analysis was applied using the IPI score as one factor, nonanaplastic PTCL remained an independent parameter (P = .0004). Although the poor prognosis of non-ALCL PTCL could be due in part to the presence of adverse prognostic factors at diagnosis, this study shows that the T-cell phenotype is an independent significant factor, which should be incorporated into the definition of prognostic groups.

    INTRODUCTION
Abstract
Introduction
Methods
Results
Discussion
References

T-CELL NON-HODGKIN'S lymphomas (NHL) are rare in Europe and the United States, where they constitute about 15% to 20% of aggressive lymphomas.1-4 They are more common in Taiwan and Japan5 and are frequently associated with human T-lymphotropic virus-I.6,7 They include T-cell lymphomas expressing an immature prethymic or thymic phenotype, classified as lymphoblastic lymphomas and T-cell lymphomas of peripheral origin, with a post-thymic CD1-, TdT- phenotype that have been selected for the study. According to morphologic and immunological criteria, all cases have been classified according to the updated Kiel classification,8 and the Revised European-American Lymphoma (REAL) classification has also distinguished other entities based on the site of origin, and/or additional phenotyping or cytogenetic features.9

The prognostic significance of the immunophenotype has been explored in several studies,2,10-12 and conflicting results have been reported concerning the outcome of peripheral T-cell lymphomas (PTCL) compared with that of B-cell lymphomas (BCL). PTCL patients were found to have equivalent10,5 or poorer prognoses than patients with BCL.11,12 We previously reported2 that PTCL were associated with a poor prognosis and that immunophenotype per se could be an independent adverse prognostic parameter for event-free survival (EFS). PTCL represent a heterogeneous group of lymphomas, and a wide variety of different histological subtypes have been recognized.8,9,13-16 According to the Kiel classification, in our series the most common PTCL is the pleomorphic medium and large-cell lymphoma (PML),8 followed by anaplastic large cell lymphoma (ALCL),17 angioimmunoblastic lymphoma (AIL),18,19 and lymphoepithelioid lymphoma. Although it was suggested that PTCL had low-grade or high-grade histological features, the prognostic significance of such a distinction has not been established.8

The International Prognostic Index (IPI) Project20 did not evaluate the influence of immunophenotype on overall survival (OS), primarily because of the limited amount of phenotypic data available and the difficulty of prospectively studying a cohort of PTCL patients large enough to ensure statistical significance. Recently, the prognostic value of immunophenotype, using the REAL classification, was evaluated with stratification of other prognostic factors.3 Although the T-cell phenotype was an independent and significant prognostic factor, it was not possible to show a statistically significant effect on OS among the different histological subtypes.

To better define the clinical outcomes of the different subtypes of T-cell lymphoma, 288 patients with a confirmed T-cell immunophenotype included in the prospective LNH87 protocol were compared with 1595 BCL patients of comparable histological grades. The aim of this study was to evaluate the prognoses of the different entities defined in the Kiel classification and to compare them with BCL patients with similar clinical characteristics according to the IPI score.

    MATERIALS AND METHODS
Abstract
Introduction
Methods
Results
Discussion
References

Patient Selection

This series included all patients with the diagnosis of PTCL confirmed by pathological review and who were registered in the LNH87 study. The LNH87 trial, conducted by the Groupe d'Etude des Lymphomes de l'Adulte (GELA), recruited from 50 participating French and Belgian centers patients who were at least 15 years old and had intermediate- or high-grade NHL, according to the Working Formulation, but were seronegative for the human immunodeficiency virus and had no previous cancer, cardiac disease, uncontrolled diabetes mellitus, or kidney failure. Patients were staged according to the Ann Arbor system. Disease dissemination was evaluated before treatment by physical examination, bone marrow (BM) biopsy, and computerized tomography scan of chest and abdomen.

The number of extranodal sites (ENS) and the largest tumor mass diameter were also determined. Performance status (PS) was based on the World Health Organization scale. The serum lactate dehydrogenase (LDH) level was expressed as the ratio over the maximal normal value. From October 1st, 1987 to April 1st, 1993, 3,232 patients were included in the LNH87 trial. At the time of analysis, 88% of the slides were available for pathological review. At the present time, 288 patients have been given the diagnosis of peripheral T-cell NHL after review of the histopathological slides and immunohistochemical analyses. Similarly, 1,595 patients were considered to have BCL, and most of them, 1,390, were diffuse large B-cell lymphomas of the categories G and H of the Working Formulation (ie, centroblastic and immunoblastic type according to the updated Kiel classification). Follicular large cell and mantle cell lymphoma were excluded from the comparison.

Treatment and Assessment of Response

Patients were stratified into 4 groups according to age and the presence or absence of the following adverse prognostic factors: (1) PS > 1; (2) >= 2 ENS; (3) tumor diameter >= 10 cm; (4) BM or central nervous system involvement. Details of the chemotherapy regimens are reported elsewhere.21,22

Group 1.   This group included 77 PTCL and 351 BCL patients less than 70 years old without any adverse prognostic factors. Patients were randomly assigned to receive 8 cycles every 3 weeks of mBACOD (Adriamycin 45 mg/m2, cyclophosphamide 600 mg/m2, vincristine 1 mg/m2, bleomycin 10 mg/m2 d1, methotrexate 200 mg/m2 d8 and d15, Decadron [Merck Sharp Dohme, Paris, France] d1-5) or 3 courses every 2 weeks of ACVB (Adriamycin [Pharmacia, Guyancourt, France] 75 mg/m2 d1, cyclophosphamide 1,200 mg/m2 d1, vindesine 2 mg/m2 d1, d5, bleomycin 10 mg d1 and d5, prednisone 60 mg/m2 d1-5) followed by the consolidation and maintenance chemotherapies of the LNH84 protocol.21

Group 2.   This group included 91 PTCL and 520 BCL patients, 15 to 55 years old, with at least one of the adverse prognostic factors. Patients were randomly assigned to receive 4 cycles of ACVB or 4 courses of NCVB (same as ACVB but with mitoxantrone 12 mg/m2 d1 instead of Adriamycin). Those in complete remission (CR) were randomized between autologous BM transplantation using CVB (cyclophosphamide 1,500 mg/m2 d1-4, Vepesid [Novartis-Pharma, Revil-Malmaison, France] 250 mg/m2 d1-4, Carmustine [BCNU] 300 mg/m2 d4) as conditioning regimen or the classical consolidation and maintenance therapy of the LNH84 protocol.22

Group 3.   Group 3 included 80 PTCL and 451 BCL patients, 55 to 70 years old, with at least one adverse prognostic factor. Patients were randomized to receive 4 cycles of ACVB followed by the consolidation and maintenance therapy of LNH84 protocol or 4 alternating induction cycles every 3 weeks of VIM3 (mitoxantrone 10 mg/m2 d1, ifosfamide 1,000 mg/m2 d1-3, Methyl-GAG 300 mg/m2 d1 and d5, Vehem [Novartis-Pharma] 100 mg/m2 d1 and d5, prednisone 60 mg/m2 d1-5, methotrexate 1,500 mg/m2 d14) and ACVB then a maintenance therapy with 4 alternating courses every 3 weeks of VIM (mitoxantrone 10 mg/m2 d1, Vepesid 150 mg/m2 d1-3, ifosfamide 1,000 mg/m2 d1-3) and ACVM (Adriamycin 50 mg/m2 d1, cyclophosphamide 750 mg/m2 d1, vindesine 2 mg/m2 d1, methotrexate 200 mg/m2 d7, d15).23

Group 4.   Group 4 included 40 PTCL and 273 BCL patients over 70 years old. They were randomly assigned to receive CVP (cyclophosphamide 750 mg/m2 d1, Vehem 75 mg/m2 d1, prednisone 40 mg/m2 d1-3) or CTVP (same as CVP plus tetrahydropyranyladriamycin 50 mg/m2 d1) for 6 cycles.24

Response to therapy was evaluated after induction therapy, which generally consisted of 4 cycles of chemotherapy. A CR was defined as the disappearance of all clinical evidence of disease and the normalization of all laboratory values, radiographs, scans, and biopsies that were abnormal before therapy. Additionally, patients with persistent computed tomographic abnormalities but regression greater than 75% of the initial tumor volume were deemed to be in CR when in CR of all other parameters. Partial remission (PR) was defined as reduction of 50% to 75% of the initial tumor volume. Treatment failure was defined by a lower response, progressive disease, or a treatment-related death.

Histological and Immunophenotypic Studies

The slides of all patients included in the LNH87 protocol that were initially diagnosed as having PTCL by three independent pathologists were reviewed again by two other independent pathologists (J.D., P.G.). Disagreements were resolved by consensus discussions, usually after additional immunostaining tests. The aims of this second review were (1) to confirm the diagnosis of PTCL and (2) to subclassify them according to the categories of the updated Kiel classification to assess their potential prognostic significance. In addition, some categories of extra nodal T-cell lymphomas recently recognized in the REAL classification mostly based on the site of origin were identified among the included PML category.9

The diagnosis of PTCL was based on both morphologic examination of slides from routinely paraffin-embedded samples stained with hematoxylin-eosin, Giemsa, and Gordon-Sweet's staining and immunophenotyping results. In all cases, immunophenotyping was performed with a panel of antibodies comprising CD20/L26, CD3, and CD45R0/UCHL1 (Dako, Glostrup, Denmark) to determine the B- or T-cell lineage, respectively, using an indirect immunoperoxidase or alkaline phosphatase antialkaline phosphatase (APAAP) method. Depending on histological subtypes, the expression of activation (CD30/BerH2, EMA, Dako), cytotoxic (TIA-1; Coulter, Hialeah, FL), Epstein-Barr virus (EBV; latent membrane protein LMP-1, CS 1-4; Dako) antigens were also tested, as well as the presence of follicular dendritic cells (CNA-42 antibody, kindly given by G. Delsol, Hopital Purpan, Toulouse, France). Furthermore, additional immunophenotyping was obtained on frozen sections for one third of the cases or for some cases by flow cytometry.

The diagnosis of the different subcategories of PTCL according to the updated Kiel classification was based on histological and phenotypic criteria.8 Lymphoblastic lymphoma, mycosis fungoides, and Sezary syndrome were excluded from the study. Briefly, the diagnosis of AIL-like required morphological and/or phenotypic evidence of follicular dendritic cells (CNA-42+) in addition to other classical cytological criteria. The diagnosis of lymphoepithelioid (Lennert's) lymphoma was assigned when the proliferation consisted of slightly pleomorphic T cells admixed with epithelioid cells but without morphological evidence of Reed Sternberg cells and follicular dendritic cells. PML included all cases characterized by some degree of pleomorphism and a large cell component. This category included a few cases with a predominance of medium-sized cells. Some of the PML cases were with extranodal presentation, which were further subclassified according to the entities of the REAL classification. For the diagnosis of T-ALCL, anaplastic morphology, T-cell phenotype, and the expression of CD30 on virtually all tumor cells was required, as previously reported.25 After additional immunostaining, 11 new cases from the LNH87 study were diagnosed as T-ALCL and put together with the 49 patients reported by Tilly et al.25 The histological distribution of the 288 cases of PTCL according to the updated Kiel classification is reported in Table 1.

 
View this table:
[in this window] [in a new window]
 
Table 1. Histological Distribution According to the Kiel Classification of the 288 PTCL Lymphomas

Statistical Analysis

Patient characteristics and CR rates were compared using the chi-squared test. Because of the low number of patients in some morphological subgroups, AIL, lymphoepithelioid, and pleomorphic small cell, which all show a predominance of small/medium-sized cell populations, were analyzed together. The three cases of immunoblastic lymphoma were included in the PML category.

Overall survival time was calculated from the date of randomization until death or last follow-up examination. EFS was calculated from the date of randomization until disease progression, relapse, or last follow-up visit.

Survival curves were estimated using the product-limit method of Kaplan-Meier26 and were compared using the log-rank test. Univariate analyses were made using the chi-squared test and log-rank test. Stepwise Cox proportional-hazards regression analysis with the OS as the dependent variable was used to adjust the effect of the T-cell phenotype for potential independent prognostic factors.27

    RESULTS
Abstract
Introduction
Methods
Results
Discussion
References

The main clinical and biological characteristics of the 288 PTCL patients with the 1,595 patients with diffuse BCL are listed in Table 2. The median age of the PTCL patients enrolled in the study was 56 years and that of BCL patients was 57 years. Several clinical parameters were significantly more prevalent in PTCL patients; male gender, advanced stage with multiple-node involvement, B symptoms, BM involvement, hepatosplenomegaly, and skin lesions. BCL patients had more localized stage and bulky disease. Significantly more PTCL patients presented with anemia, hypereosinophilia, and hypergammaglobulinemia. A comparison of the main clinical characteristics of the 228 non-ALCL PTCL patients with the 60 patients with T-ALCL are reported in Table 3. These latter tend to have more localized stage with a more favorable IPI score.

 
View this table:
[in this window] [in a new window]
 
Table 2. Clinical Characteristics of PTCL and Diffuse BCL Patients

 
View this table:
[in this window] [in a new window]
 
Table 3. Clinical Characteristics of T-Nonanaplastic Large-Cell Lymphoma and T-Anaplastic Large-Cell Lymphoma Patients

Response to Treatment

The CR rates were 54% and 63% for T- and B-cell NHL, respectively (P = .005). Partial responses and failures were observed in 20% and 14% of T-cell and 18% and 10% of B-cell NHL. During the induction phase, respectively, 11% and 9% of the patients died. According to univariate analysis, factors affecting the response rate were similar for the T and B subgroups. For T- and B-cell NHL, the CR rates according to the prognostic subgroups defined by the IPI score were similar except for patients with greater than or equal to 3 factors 35% and 52%. Comparisons between other subgroups are reported in Table 3. It should be noted that T-ALCL patients had the best CR rate (72%), which was significantly different from that of the non-ALCL PTCL (49%) (P = .002).

Survival

The overall 5-year survival rates (Fig 1)differed between PTCL (41%) and BCL (52%) (P = .0004). Comparison between B- and T-cell lymphoma patients was made within the different subgroups of the international prognostic index, and the results are reported in Table 3. A better survival was observed for BCL patients, but differences were significant only for patients with greater than or equal to 2 factors. Comparison between stage III to IV was also significant with a 5-year survival rate of 43% and 33% for BCL and PTCL, respectively (P = .01), but was not significant for stage I to II, 66% and 69% (P = .6). Survival was also analyzed according to the histological subtypes defined by the Kiel classification (Table 4). First, ALCL had a 5-year OS of 64%, which was better than that of any subgroup of T- or B-cell NHL and was superior to non-ALCL PTCL (Fig 2). Second, PML and immunoblastic T-cell lymphoma had significantly lower survival rates when compared with diffuse large (centroblastic and immunoblastic) BCL patients. Third, the remaining subgroup including AIL-like, lymphoepitheliod, and pleomorphic small-cell lymphomas with a 31% probability of survival (Fig 3) had a worse outcome than diffuse mixed B lymphomas (46%). However, this survival was similar to that of the other PML T-cell lymphoma patients (Fig 4). Using non-ALCL T-cell lymphoma as the variable, the international prognostic index was used to stratify the patients (Fig 5). For non-ALCL PTCL patients the OS probability for patients with IPI scores of 0, 1, 2, or >= 3 were, respectively, 64%, 56%, 34%, and 22%. The difference was significant when compared with BCL patients except for an IPI 1 score. The 5-year EFS was 32% for PTCL and 45% for BCL (P = .0001).


View larger version (12K):
[in this window]
[in a new window]
 
Fig 1. Overall survival of 288 PTCL patients compared with 1,595 diffuse BCL patients.

 
View this table:
[in this window] [in a new window]
 
Table 4. Outcome of PTCL Categories Compared With BCL Patients


View larger version (14K):
[in this window]
[in a new window]
 
Fig 2. Overall survival of 228 non-ALCL cell and 60 T-ALCL lymphoma patients compared with 1,595 diffuse BCL patients.


View larger version (11K):
[in this window]
[in a new window]
 
Fig 3. OS of 68 AIL patients, 12 lymphoepithelioid, and 3 pleomorphic small-cell lymphoma patients.


View larger version (9K):
[in this window]
[in a new window]
 
Fig 4. Comparison of OS of the two main groups of PTCL: (A) n = 83; AIL, lymphoepithelioid, pleomorphic small-cell lymphoma patients and (B) n = 145 PML, immunoblastic patients.


View larger version (11K):
[in this window]
[in a new window]
 
Fig 5. OS of non-ALCL T-cell lymphoma patients grouped according to the IPI score.

Because of the better survival advantage for T-ALCL, multivariate analysis was performed only on patients with non-ALCL PTCL and BCL. Five factors adversely and significantly influenced survival: age greater than 60 years, disseminated stage, elevated LDH, performance status, and non-ALCL T-cell lymphoma (P = .0001). Treatment arm was not a significant factor. A second multivariate analysis was done using the IPI (age, stage, LDH, PS) as one factor. Non-ALCL T-cell lymphoma remained highly significant (P = .0004).

    DISCUSSION
Abstract
Introduction
Methods
Results
Discussion
References

This large series of PTCL further emphasizes the morphological heterogeneity of these neoplasms. Classification on the basis of morphology and immunophenotyping is still subject to controversy because of numerous entities included under the name of PTCL. The clear identification of ALCL T-cell lymphomas on the basis of morphology, CD30 antigen expression,17 a common cytotoxic profile,28,29 and a better outcome25 clarifies the situation by separating these lymphomas from the others. Since its recognition in 1978 as an immune disorder, there is also evidence that AIL-like T-cell lymphoma constitutes a distinct PTCL entity, with morphological, phenotypic, and clinical features and a peculiar pattern of EBV30 and cytokines expression.31 In the present study, we further confirm that lymphoepithelioid (Lennert's) lymphoma and T-zone lymphoma are very rare morphological subtypes, often difficult to distinguish from epithelioid-cell-rich AIL or other categories of PTCL.9 About half of the present cases were classified as PML based on the predominance of medium and/or large neoplastic cells. This PML category included several cases of more recently recognized extranodal lymphomas, eg, nasal T-natural killer (NK)-cell lymphomas,32,33 intestinal T-cell lymphomas,34 subcutaneous panniculitis-like T-cell NHL,35 and hepatosplenic gamma-delta T-cell lymphoma.36,37 Altogether, these subgroups represented about 20% of the PML category.

The cytological distinction between high- and low-grade malignancies did not translate into a different outcome for non-ALCL T-cell lymphoma8 in this large series representative of the lymphoma population encountered by clinicians in Europe. However, the selection of cases eliminated T-CLL, mycosis fungoides, and Sezary syndrome.

Using the updated Kiel classification, only three major subgroups (PML, AIL, and ALCL) could be considered sufficiently common to be analyzed in clinical trials. For the other described entities, their prognoses seemed to be rather poor, whether or not they presented with nodal or extranodal disease. In the absence of new data, they should be treated in the same way as the major subgroups, PML or AIL.

Analysis of clinical parameters showed that T-cell NHL more often presented with disseminated disease and extranodal presentation than B-cell NHL. When patients were stratified according to their IPI score, 45% of T-lymphoma patients had three or more adverse prognostic factors, which was significantly different from the distribution in BCL (37%). The high degree of BM involvement (31%) was associated with anemia and thrombopenia. Eosinophilia and hypergammaglobulinemia were more often encountered in AIL. Severe disease at the time of presentation had previously been described2,3 and might explain the lower CR rate observed in non-ALCL T-cell lymphoma as compared with B-cell NHL. Not surprisingly, this poorer response was translated into shorter OS and EFS. These results are in agreement with our previous study2 but were not found in other retrospective studies.5,10,11 In fact in the study of Kwak et al10 based on 21 T-cell and 77 B-cell NHL, there was a trend favoring the better outcome of T-cell lymphomas.

In our study, patients were enrolled in a prospective randomized trial, and 88% of histological material was available for immunophenotyping. Because of the size of this population, it was possible to separate and analyze each of the major subgroups defined by the updated Kiel classification and to compare them with B-cell NHL. Only ALCL T-cell lymphomas had significantly better CR rates and survival, and thus should be clearly separated from the other groups for the analysis of the significance of immunophenotype as a prognostic factor. A similar trend was observed by Melnyk et al, although it could not reach a statistically significant difference with only 10 patients with T-ALCL.3 With risk stratification according to the IPI score, the OS was significantly worse for non-ALCL T lymphomas, but this difference was mainly found with an IPI score greater than or equal to 2, even when all PTCL were analyzed together. In multivariate analysis, non-ALCL T-cell character appeared to be an independent adverse prognostic factor. Association in Cox's analysis with other well-known parameters such as age, performance status, and disseminated stage lead us to further investigate non-ALCL T-cell phenotyping and to consider IPI as a single parameter in a stratified analysis. Non-ALCL T-cell lymphoma remained significant, thereby allowing it to be considered as an independent adverse prognostic factor.

The poor prognosis of peripheral T-cell lymphoma has been reported in most series.2,3,5,11,38 With the intensive regimens used in the LNH87 study, the 41% 5-year survival rate is similar to those reported by others.2,10,11,39,40 The same control arm ACVB was used until 70 years of age, and there was no difference between treatment arms in each group for PTCL. However, the 23% 5-year survival rate for patients with three or more adverse prognostic factors cries out for new strategies. In one arm of the LNH87 trial already reported,22 autologous stem-cell transplantation was performed after CR. Interestingly, for 16 PTCL patients submitted to this procedure the probability of survival was not different from that of BCL patients. However, the low CR rate hampered such an approach for the majority of them. Various chemotherapy regimens have been tested39,40 and, until now, have proven to be unsuccessful in modifying outcome. Curiously, other agents such as interferon-alpha ,41 13-cis-retinoid acid,42 interleukin-2,43 or cyclosporine44 have shown some degree of transient activity in refractory disease. Nevertheless, treatment of patients with several adverse prognostic factors remains unsolved, and most PTCL should be included in prospective trials testing innovative approaches.

    FOOTNOTES

   Submitted October 15, 1997; accepted March 5, 1998.
   Supported in part by the Ligue Contre le Cancer.
   Address reprint requests to Christian Gisselbrecht, MD, Institut d'Hématologie, Hôpital Saint-Louis, 1, Avenue Claude-Vellefaux, 75475 Paris Cedex 10, France.
   The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" is accordance with 18 U.S.C. section 1734 solely to indicate this fact.

    ACKNOWLEDGMENT

The authors acknowledge Catherine Balmale and Catherine Belorgey for their invaluable technical assistance, Catherine Barli for preparing the manuscript, and they thank the following clinicians and pathologists who actively participated in the study: I. Abdalsamad, M.F. d'Agay, C. Allard, R. Angonin, J. d'Anjou, B. Audhuy, J. Audouin, G. Auzanneau, A.C. Baglin, C. Bailly, Y. Bastion, E. Baumelou, P. Bensimon, F. Berger, P. Biron, A.M. Blaise, M. Blanc, F. Boman-Ferrand, A. Boehn, J. Boniver, M. Bordes, D. Bordessoule, A. Bosly, R. Bouabdallah, S. Boucheron, J. Bouvier, P. Brice, J. Brière, N. Brousse, P. Brousset, P.A. Bryon, D. Caillot, J.P. Carbillet, R.O. Casasnovas, T. Caulet, D. Cazals, F. Charlotte, L. Charvillat, A.M. Chesneau, B. Christian, B. Coiffier, T. Conroy, J.F. Cordier, C. Cordonnier, J.P. Clauvel, E. Deconinck, M. Delage, A. Delannoy, M. Delos, G. Delsol, A. Devidas, J. Diebold, M. Diviné, H. Dombret, C. Doyen, H. Duplay, B. Dupriez, C. Duval, J.C. Eisenmann, J.M. Emberger, B. Epardeau, B. Fabiani, P. Felman, J.P. Fermand, C. Fermé, A. Ferrand, M. Ffrench, M. Fievez, Y. Fonck, N. Froment, J. Gabarre, P. Galian, O. Gasser, P. Gaulard, C. Gisselbrecht, B. Gosselin, H. Guy, D. Guyotat, C. Haioun, J. Hamels, R. Herbrecht, O. Hopfner, N. Horschowski, F. Huguet, P. Jacomy, J. Jaubert, R. Jeandel, Y. Kerneis, J.P. Knopf, M. Kuentz, E. Labouyrie, B. Lancien, G. Laurent, A. Lavergne, C. Lavignac, V. Leblond, M. Lecomte-Houke, P. Léderlin, F. Lejeune, M.B. Leger-Ravet, R. Loire, R. Marcellin, J.P. Marolleau, G. Marit, C. Martin, C. Marty-Double, A. De Mascarel, S. Méhaut, J.P. Merlio, C. Merignargues, J.M. Micléa, J.L. Michaux, M. Monconduit, P. Morel, F. Morvan, J.F. Mosnier, G. Nédellec, C. Netter-Pinon, H. Noel, C. Nouvel, M. Patey, P.Y. Peaud, G. Perie, M. Peuchmaur, T. Petrella, B. Pignon, C. Platini, M. Pluot, J.P. Pollet, E. Pujade-Lauraine, M. Raphael, M.C. Raymond-Gelle, J. Reiffers, F. Reyes, M. Rochet, J.F. Rossi, A.M. Roucayrol, A. Rozenbaum, G. Salles, H. Schill, C. Sebban, M. Simon, P. Solal-Céligny, P. Straub, E. Suc, L. Sutton, M. Symann, G. Tertian, S. Thiebaut, A. Thyss, H. Tilly, P. Travade, V. Trillet, J.P. Vernant, D. Wendum, and L. Xerri.

    REFERENCES
Abstract
Introduction
Methods
Results
Discussion
References

1. Greer JP, York JC, Cousar JB, Mitchell RT, Flexner JM, Collins RD, Stein RS: Peripheral T-cell lymphoma: A clinicopathologic study of 42 cases. J Clin Oncol 2:788, 1984[Abstract]

2. Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J, for the GELA: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH84 regimen. Ann Oncol 1:45, 1990[Abstract/Free Full Text]

3. Melnyk A, Rodriguez A, Pugh WC, Cabanillas F: Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89:4514, 1997[Abstract/Free Full Text]

4. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. Blood 89:3909, 1997[Abstract/Free Full Text]

5. Cheng AL, Chen YC, Wang CH, Su IJ, Hsieh HC, Chang JY, Hwang WS, Su WC, Liu TW, Tien HF, Tsai W, Shen MC, Liu CH: Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades. Should peripheral T-cell lymphoma be considered separately? J Clin Oncol 7:725, 1989[Abstract]

6. Broder S, Bunn PA, Jaffe ES, Blattner W, Gallo RC, Wong-Staal F, Waldmann TA, DeVita VT Jr: T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med 100:543, 1984

7. Shimoyama M: Lymphoma and leukemia of T-lymphocytes , in Sommers SC, Rosen P (eds): Pathology Annual 1981 (part 2). New York, NY, Appleton-Century-Crofts , 1981 , p 155

8. Stansfeld AG, Diebold J, Kapanci Y, Rilke F, Kelenyi G, Sundstrom C, Lennert K, Van Unnik JAM, Mioduszewska O, Wright DH: Updated Kiel classification for lymphomas. Lancet 1:292, 1988[Medline] [Order article via Infotrieve]

9. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary M, Delsol G, De Wolf-Peeters C, Falini B, Garter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994[Free Full Text]

10. Kwak LW, Wilson M, Weiss LM, Goggett R, Dorfman RF, Warnke RA, Horning SJ: Similar outcome of treatment of B-cell and T-cell diffuse large cell lymphomas: The Stanford experience. J Clin Oncol 9:1426, 1991[Abstract]

11. Armitage JO, Vose JM, Linder J, Weisenburger D, Harrington D, Casey J, Bierman P, Sorensen S, Hutchins M, Moravec DF, Howe D, Dowling MD, Mailliard J, Johnson S, Pevnick W, Packard WM, Okerbloom J, Thompson RF, Langdon RM, Soori G, Peterson C, Purtilo D: Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol 7:1783, 1989[Abstract]

12. Lippman SM, Miller TP, Spier CM, Slymen DJ, Grogan TM: The prognostic significance of the immunotype in diffuse large-cell lymphoma: A comparative study of the T-cell and B-cell phenotype. Blood 72:436, 1988[Abstract/Free Full Text]

13. Weiss LM, Crabtree GS, Rouse RV, Warnke RA: Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas. Am J Pathol 118:316, 1985[Abstract]

14. Liang R, Todd D, Chan TK, Wong KL, Ho F, Loke SL: Peripheral T-cell lymphoma. J Clin Oncol 5:750, 1987[Abstract/Free Full Text]

15. Weisenburger DD, Linder J, Armitage JO: Peripheral T-cell lymphoma: A clinicopathologic study of 42 cases. Hematol Oncol 5:175, 1987[Medline] [Order article via Infotrieve]

16. Pinkus GS, O'Hara CJ, Said JW: Peripheral post-thymic T-cell lymphomas: A spectrum of disease. Cancer 65:971, 1990[Medline] [Order article via Infotrieve]

17. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K: The expression of the Hodgkin's disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848, 1985[Abstract/Free Full Text]

18. Tobinai K, Minato K, Ohtsu T, Murai K, Kagami Y, Miwa M, Watanabe S, Shimoyama M: Clinicopathologic, immunophenotypic and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. Blood 72:1000, 1988[Abstract/Free Full Text]

19. Nathwani BN, Rappaport H, Moran EM, Pangalis GA, Hun Kim: Malignant lymphoma arising in angioimmunoblastic lymphadenopathy. Cancer 41:578, 1978[Medline] [Order article via Infotrieve]

20. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987, 1993[Abstract/Free Full Text]

21. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N: LNH84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018, 1989[Abstract]

22. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Brière J, Gaulard P, Reyes F: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 15:1131, 1997[Abstract/Free Full Text]

23. (abstr) Bosly A, Lepage E, Dupriez B, Herbrecht R, Fillet G, Divine M, Nouvel C, Tilly H, Bordessoule D, Gaulard P, Gisselbrecht C: Alternance of chemotherapy does not improve results in aggressive non-Hodgkin's lymphoma: A prospective randomized study on 884 patients LNH87 protocol group 3: A GELA study. Br J Haematol 83:546, 1996

24. Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D, Sebban C, Blanc M, Tilly H, Lederlin P, Deconinck E, Salles B, Dumontet C, Brière J, Coiffier B: Elderly patients with aggressive lymphoma survive longer if treated with a curative intent. A GELA study on 453 patients older than 69 years. J Clin Oncol 15:2945, 1997[Abstract]

25. Tilly H, Gaulard P, Lepage E, Dumontet C, Diebold J, Plantier I, Berger F, Symann M, Petrella T, Lederlin P, Brière J: Primary anaplastic large-cell lymphoma in adults. Clinical presentation, immunophenotype, and outcome. Blood 90:3727, 1997[Abstract/Free Full Text]

26. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457, 1958

27. Cox DR: Regression models and life-tables. J R Stat Soc 34:187, 1972

28. Krenacs L, Wellmann A, Sorbara L, Himmelmann AW, Bagdi E, Jaffe ES, Raffeld M: Cytotoxic cell antigen expression in anaplastic large cells lymphoma of T- and null-cell type and Hodgkin's disease: Evidence for distinct cellular origin. Blood 89:980, 1997[Abstract/Free Full Text]

29. Foss ES, Anagnostopoulos I, Araujo I, Assaf C, Demel G, Kummer JA, Hummel M, Stein H: Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 88:4005, 1996[Abstract/Free Full Text]

30. Weiss LM, Jaffe ES, Liu XF, Chen YY, Shibata D, Medeiros LJ: Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy-like lymphoma. Blood 79:1789, 1992[Abstract/Free Full Text]

31. Foss HD, Anagnostopoulos I, Herbst H, Grebe M, Ziemann K, Hummel M, Stein H: Patterns of cytokine gene expression in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 85:2862, 1995[Abstract/Free Full Text]

32. Jaffe ES, Chan JKC, Ih Jen Su, Frizzera G, Mori S, Feller AC, Ho FCS: Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis and epidemiology. Am J Surg Pathol 20:103, 1996[Medline] [Order article via Infotrieve]

33. Kanavaros P, Leses MC, Brière J, Divine M, Galateau, Joab I, Bosq J, Farcet JP, Reyes F, Gaulard P: Nasal T-cell lymphoma: A clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 81:2688, 1993[Abstract/Free Full Text]

34. Schmitt-Graff A, Hummel M, Zemlin M, Schneider T, Ulrich R, Heise W, Zeit M, Riecken EO, Stein H: Intestinal T-cell lymphoma: A reassessment of cytomorphological and phenotypic features in relation to patterns of small bowel remodeling. Virchows Arch 429:27, 1996[Medline] [Order article via Infotrieve]

35. Gonzalez CL, Medeiros LJ, Braziel RM, Jaffe ES: T-cell lymphoma involving subcutaneous tissue: A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am Surg J Pathol 15:17, 1991

36. Gaulard P, Bourquelot P, Kanavaros P, Haioun C, Le Couedic JP, Divine M, Goossens M, Zafrani ES, Farcet JP, Reyes F: Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gd T-cell lymphomas. Am J Pathol 137:617, 1990[Abstract]

37. Cooke CB, Krenacs L, Stetler-Stevensen M, Greiner TC, Raffeld M, Kingma DW, Abruzzo L, Frantz C, Kaviani M, Jaffe ES: Hepatosplenic T-cell lymphoma: A distinct clinicopathologic entity of cytotoxic gd T-cell origin. Blood 88:4265, 1996[Abstract/Free Full Text]

38. Archimbaud E, Coiffier B, Bryon PA, Vasselon C, Brizard CP, Viala JJ: Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer 59:208, 1987[Medline] [Order article via Infotrieve]

39. Siegert W, Agthe A, Griesser H, Schwerdtfeger R, Brittinger G, Engelhard M, Kuse R, Tiemann M, Lennert K, Huhn D, for the Kiel Lymphoma Study Group: Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COMBLAM/IMVP-16 regimen. Ann Intern Med 117:364, 1992

40. Karakas T, Bergman L, Stutte HJ, Jäger E, Knuth A, Weidmann E, Mitrou PS, Hoelzer D: Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high grade B-cell lymphomas. Leuk Lymphoma 24:121, 1996[Medline] [Order article via Infotrieve]

41. Siegert W, Nerl C, Meuthen I, Zahn T, Brack N, Lennert J, Hunn D: Recombinant human interferon-a in the treatment of angioimmunoblastic lymphadenopathy: Results in 12 patients. Leukemia 10:892, 1991

42. Cheng AL, Chen CC, Tien HF, Lay JD, Chen BR, Pu YS, Hong RL, Shen MC, Wang CH, Chen YC: Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study. J Clin Oncol 12:1185, 1994[Abstract/Free Full Text]

43. Gisselbrecht C, Maraninchi D, Pico JL, Milpied N, Coiffier B, Divine M, Tiberghien P, Bosly A, Tilly H, Boulat O, Brandely M: Interleukin-2 treatment in lymphoma: A phase II multicenter study. Blood 83:2081, 1994[Abstract/Free Full Text]

44. Murayama T, Imoto S, Takahashi T, Ito M, Matozaki S, Nakagawa T: Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin A. Cancer 69:2567, 1992[Medline] [Order article via Infotrieve]


© 1998 by The American Society of Hematology.
 
0006-4971/98/92-0032$3.00/0

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
M. Nickelsen, M. Ziepert, S. Zeynalova, B. Glass, B. Metzner, M. Leithaeuser, H.K. Mueller-Hermelink, M. Pfreundschuh, and N. Schmitz
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Ann. Onc., July 1, 2009; (2009) mdp211v1.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Reimer, T. Rudiger, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Einsele, H. K. Muller-Hermelink, and M. Wilhelm
Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study
J. Clin. Oncol., January 1, 2009; 27(1): 106 - 113.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
F. Foss
Treatment Approaches for Aggressive T-cell Lymphomas
ASCO Educational Book, January 1, 2009; 2009(1): 480 - 485.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
C Agostinelli, P P Piccaluga, P Went, M Rossi, A Gazzola, S Righi, T Sista, C Campidelli, P L Zinzani, B Falini, et al.
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies
J. Clin. Pathol., November 1, 2008; 61(11): 1160 - 1167.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
International T-Cell Lymphoma Project
International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes
J. Clin. Oncol., September 1, 2008; 26(25): 4124 - 4130.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Le Gouill, N. Milpied, A. Buzyn, R. Peffault De Latour, J.-P. Vernant, M. Mohty, M.-P. Moles, K. Bouabdallah, C.-E. Bulabois, J. Dupuis, et al.
Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
J. Clin. Oncol., May 10, 2008; 26(14): 2264 - 2271.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Mercadal, J. Briones, B. Xicoy, C. Pedro, L. Escoda, C. Estany, M. Camos, L. Colomo, I. Espinosa, S. Martinez, et al.
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma
Ann. Onc., May 1, 2008; 19(5): 958 - 963.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Mourad, N. Mounier, J. Briere, E. Raffoux, A. Delmer, A. Feller, C. J. L. M. Meijer, J.-F. Emile, R. Bouabdallah, A. Bosly, et al.
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
Blood, May 1, 2008; 111(9): 4463 - 4470.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Moarbess, H. El-Hajj, Y. Kfoury, M. E. El-Sabban, Y. Lepelletier, O. Hermine, C. Deleuze-Masquefa, P.-A. Bonnet, and A. Bazarbachi
EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma
Blood, April 1, 2008; 111(7): 3770 - 3777.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Kyriakou, C. Canals, A. Goldstone, D. Caballero, B. Metzner, G. Kobbe, H.-J. Kolb, J. Kienast, P. Reimer, J. Finke, et al.
High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome--Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
J. Clin. Oncol., January 10, 2008; 26(2): 218 - 224.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
A. R. Shustov and K. J. Savage
Does High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation Have a Role in the Primary Treatment of Peripheral T-Cell Lymphomas?
Hematology, January 1, 2008; 2008(1): 39 - 41.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
L. de Leval and P. Gaulard
Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas
Hematology, January 1, 2008; 2008(1): 272 - 279.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
K. J. Savage
Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas
Hematology, January 1, 2008; 2008(1): 280 - 288.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
N. Schmitz, P. Dreger, B. Glass, and A. Sureda
Allogeneic transplantation in lymphoma: current status
Haematologica, November 1, 2007; 92(11): 1533 - 1548.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Rodriguez-Antona, S. Leskela, M. Zajac, M. Cuadros, J. Alves, M. V. Moneo, C. Martin, J. C. Cigudosa, A. Carnero, M. Robledo, et al.
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas
Blood, November 1, 2007; 110(9): 3345 - 3351.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Kako, K. Izutsu, Y. Ota, Y. Minatani, M. Sugaya, T. Momose, K. Ohtomo, Y. Kanda, S. Chiba, T. Motokura, et al.
FDG-PET in T-cell and NK-cell neoplasms
Ann. Onc., October 1, 2007; 18(10): 1685 - 1690.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Gallamini, F. Zaja, C. Patti, A. Billio, M. R. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, et al.
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Blood, October 1, 2007; 110(7): 2316 - 2323.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Cuadros, S. S. Dave, E. S. Jaffe, E. Honrado, R. Milne, J. Alves, J. Rodriguez, M. Zajac, J. Benitez, L. M. Staudt, et al.
Identification of a Proliferation Signature Related to Survival in Nodal Peripheral T-Cell Lymphomas
J. Clin. Oncol., August 1, 2007; 25(22): 3321 - 3329.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
J. Rodriguez, E. Conde, A. Gutierrez, J. J. Lahuerta, R. Arranz, A. Sureda, J. Zuazu, A. F. de Sevilla, M. Bendandi, C. Solano, et al.
The adjusted International Prognostic Index and {beta}-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma
Haematologica, August 1, 2007; 92(8): 1067 - 1074.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J Rodriguez, E Conde, A Gutierrez, R Arranz, A Leon, J Marin, M Bendandi, C Albo, M. Caballero, and On behalf of the Grupo Espanol de Linfomas/Traspla
The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience
Ann. Onc., April 1, 2007; 18(4): 652 - 657.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Dupuis, J.-F. Emile, N. Mounier, C. Gisselbrecht, N. Martin-Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, et al.
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study
Blood, December 15, 2006; 108(13): 4163 - 4169.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Went, C. Agostinelli, A. Gallamini, P. P. Piccaluga, S. Ascani, E. Sabattini, F. Bacci, B. Falini, T. Motta, M. Paulli, et al.
Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score
J. Clin. Oncol., June 1, 2006; 24(16): 2472 - 2479.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. P. Greer
Therapy of Peripheral T/NK Neoplasms
Hematology, January 1, 2006; 2006(1): 331 - 337.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. Mahadevan, C. Spier, K. Della Croce, S. Miller, B. George, C. Riley, S. Warner, T. M. Grogan, and T. P. Miller
Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures
Mol. Cancer Ther., December 1, 2005; 4(12): 1867 - 1879.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Neumann, C. Wagner, K.-D. Preuss, B. Kubuschok, C. Schormann, S. Stevanovic, and M. Pfreundschuh
Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells
Blood, November 1, 2005; 106(9): 3105 - 3113.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
W.-Y. Au, S.-Y. Ma, C.-S. Chim, C. Choy, F. Loong, A. K. W. Lie, C. C. K. Lam, A. Y. H. Leung, E. Tse, C.-C. Yau, et al.
Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years
Ann. Onc., February 1, 2005; 16(2): 206 - 214.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
K. J. Savage
Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types)
Hematology, January 1, 2005; 2005(1): 267 - 277.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
N. Mounier, C. Gisselbrecht, J. Briere, C. Haioun, P. Feugier, F. Offner, C. Recher, A. Stamatoullas, F. Morschhauser, M. Macro, et al.
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Ann. Onc., December 1, 2004; 15(12): 1790 - 1797.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
K. J. Savage, M. Chhanabhai, R. D. Gascoyne, and J. M. Connors
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
Ann. Onc., October 1, 2004; 15(10): 1467 - 1475.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Ishida, H. Inagaki, A. Utsunomiya, Y. Takatsuka, H. Komatsu, S. Iida, G. Takeuchi, T. Eimoto, S. Nakamura, and R. Ueda
CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, Unspecified
Clin. Cancer Res., August 15, 2004; 10(16): 5494 - 5500.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. Mounier, C. Gisselbrecht, J. Briere, C. Haioun, P. Feugier, F. Offner, C. Recher, A. Stamatoullas, F. Morschhauser, M. Macro, et al.
Prognostic Factors in Patients With Aggressive Non-Hodgkin's Lymphoma Treated by Front-Line Autotransplantation After Complete Remission: A Cohort Study by the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol., July 15, 2004; 22(14): 2826 - 2834.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Corradini, A. Dodero, F. Zallio, D. Caracciolo, M. Casini, M. Bregni, F. Narni, F. Patriarca, M. Boccadoro, F. Benedetti, et al.
Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells
J. Clin. Oncol., June 1, 2004; 22(11): 2172 - 2176.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Enblad, H. Hagberg, M. Erlanson, J. Lundin, A. P. MacDonald, R. Repp, J. Schetelig, G. Seipelt, and A. Osterborg
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
Blood, April 15, 2004; 103(8): 2920 - 2924.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Gallamini, C. Stelitano, R. Calvi, M. Bellei, D. Mattei, U. Vitolo, F. Morabito, M. Martelli, E. Brusamolino, E. Iannitto, et al.
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
Blood, April 1, 2004; 103(7): 2474 - 2479.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
E. Weidmann, M. Gramatzki, M. Wilhelm, and P. S. Mitrou
Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting
Ann. Onc., March 1, 2004; 15(3): 369 - 374.
[Full Text] [PDF]


Home page
BloodHome page
K. Izutsu, Y. Kanda, H. Ohno, H. Sao, H. Ogawa, Y. Miyazaki, K. Kawa, Y. Kodera, S. Kato, Y. Morishima, et al.
Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program
Blood, March 1, 2004; 103(5): 1955 - 1960.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. Rodriguez, M. D. Caballero, A. Gutierrez, J. Marin, J. J. Lahuerta, A. Sureda, E. Carreras, A. Leon, R. Arranz, A. Fernandez de Sevilla, et al.
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience
Ann. Onc., December 1, 2003; 14(12): 1768 - 1775.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. W. Bekkenk, M. H. Vermeer, P. M. Jansen, A. M. W. van Marion, M. R. Canninga-van Dijk, P. M. Kluin, M.-L. Geerts, C. J. L. M. Meijer, and R. Willemze
Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients
Blood, September 15, 2003; 102(6): 2213 - 2219.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Gisselbrecht, E. Lepage, T. Molina, B. Quesnel, G. Fillet, P. Lederlin, B. Coiffier, H. Tilly, J. Gabarre, F. Guilmin, et al.
Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma
J. Clin. Oncol., May 15, 2002; 20(10): 2472 - 2479.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. Mounier, D. Simon, C. Haioun, P. Gaulard, C. Gisselbrecht, and I. Khouri
Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas
J. Clin. Oncol., March 1, 2002; 20(5): 1426 - 1427.
[Full Text] [PDF]


Home page
Ann OncolHome page
T. Rudiger, D. D. Weisenburger, J. R. Anderson, J. O. Armitage, J. Diebold, K. A. MacLennan, B. N. Nathwani, F. Ullrich, and H. K. Muller-Hermelink
Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project
Ann. Onc., January 19, 2002; 13(1): 140 - 149.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. P. Greer, M. C. Kinney, and T. P. Loughran Jr.
T Cell and NK Cell Lymphoproliferative Disorders
Hematology, January 1, 2001; 2001(1): 259 - 281.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. Wirth, H. M. Prince, M. Wolf, U. Machida, M. Kami, H. Hirai, N. Mounier, C. Gisselbrecht, E. Lepage, C. Kosmas, et al.
Treatment of Intermediate-Grade and High-Grade Non-Hodgkin's Lymphoma
N. Engl. J. Med., November 12, 1998; 339(20): 1475 - 1477.
[Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gisselbrecht, C.
Right arrow Articles by Diebold, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gisselbrecht, C.
Right arrow Articles by Diebold, J.
Related Collections
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020